“…Current evidence suggests that more than 1.5 billion people will bear the health and economic burden of hypertension in the coming years, which predicts that a range of diseases attributable to hypertension will also be a constant threat to public health in everyday life, particularly cardiovascular disease (CVD) and chronic kidney disease (CKD) (2). Multiple studies from 2016 to 2023 have shown that the global disease burden of CVD, CKD, and cardiovascular death due to hypertension continues to increase, with a study from southwestern China predicting that a 25% reduction in the prevalence of high systolic blood pressure (SBP) by 2030 would result in a reduction of 26,200 and 8,000 cases of CVD and CKD, respectively, and a reduction of cardiovascular mortality and CKD mortality by 32.8 and 16%, respectively (3)(4)(5)(6)(7)(8). These data suggest that the burden of a series of diseases caused by hypertension remains very heavy, and the formulation of high-quality prevention, management and treatment strategies for hypertension often fail to address the underlying problem, so early screening and intervention of controllable risk factors for hypertension from the source is particularly important for reducing the incidence, prevalence and mortality of hypertension and related diseases.…”